Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706987 | 1.00 | L3MBTL1 (0.61) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL8242593 | 0.93 | L3MBTL1 (0.58) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL2251586 | 0.93 | L3MBTL1 (0.58) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL27584197 | 0.93 | L3MBTL1 (0.65) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL27630597 | 0.92 | L3MBTL1 (0.52) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL16509378 | 0.89 | L3MBTL1 (0.61) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL11631569 | 0.88 | L3MBTL1 (0.67) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL11631574 | 0.88 | L3MBTL1 (0.67) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL10829643 | 0.88 | L3MBTL1 (0.50) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL10829650 | 0.88 | L3MBTL1 (0.50) | L3MBTL1HSD17B10KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117625710-A | Preparation method of (S) -5-oxo piperidine-2-carboxylic ester | 北京理工大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-114456170-B | Preparation method of stable isotope labeled methotrexate internal standard reagent | 谱同生物医药科技(常州)有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-6962920-B2 | Pyrimidine derivatives and methods of making and using these derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2004-02-26 | — | — | US | disclosed |
| US-6696455-B1 | NITROGEN COMPOUNDS SUCH AS 6-CHLORO-2-METHYL-4-OXO-PYRIDO (3,2-D)PYRIMIDINE USED AS ANTICARCINOGENIC AGENTS AND/OR FOR PROPHYLAXIS OF INFECTIONS CAUSED BY PNEUMOCYSTIS OR TOXOPLASMA | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2004-02-24 | — | — | US | disclosed |
| US-6537999-B2 | Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-03-25 | — | — | US | disclosed |
| US-6420370-B1 | ANTITUMOR, ANTIBIOTIC, ANTIMALARIAL, ANTIFUNGAL OR ANTIPROTOZOAL AGENTS, OR AS SYNERGISTIC AGENTS ENZYME INHIBITORS | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-07-16 | — | — | US | disclosed |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2002-05-02 | — | — | US | disclosed |
| US-6103727-A | RESISTING AND TREATING PNEUNOCYSTIS CARINII AND TOXOPLASMOSIS GONDII INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; AUTOMIMMUNE DISEASES; AIDS; ANTICARCINOGENIC,-TUMOR,-PROTAZOA AGENTS; MALARIA; FUNGICIDES; SYNERGISTIC WITH SULFONAMIDES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-15 | — | — | US | disclosed |
| US-6096750-A | Furopyrimidines and methods of making and using the same derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-01 | — | — | US | disclosed |
| US-5958930-A | TREATING CANCER, AND SECONDARY INFECTIONS CAUSED BY PNEUMOCYSTIS CARINII AND TOXOPLASMOSIS GONDII IN IMMUNOCOMPROMISED PATIENTS. | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-09-28 | — | — | US | disclosed |
| US-5877178-A | AIDS THERAPY | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | L3MBTL1 2427/4885HSD17B10 4080/4885KDM4E 2353/4885 |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | L3MBTL1 2427/4885HSD17B10 4080/4885KDM4E 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.